Publications by authors named "G A Freyer"
Background: Ribociclib + endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA trials in patients with HR+ /HER2 - advanced breast cancer (ABC). We report efficacy, safety, and patient-reported outcomes (PROs) across age groups, including older patients, in these trials.
Methods: Data from the MONALEESA-2, -3, and -7 trials for pre- and postmenopausal patients receiving first-line treatment for ABC were pooled and analyzed by age (<65y, 65-74y, and ≥75y).
Background: The phase III PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. Final overall survival (OS) results are reported.
View Article and Find Full Text PDFArticle Synopsis
- Healthcare professionals are addressing challenges related to drug-related problems (DRPs) in patients undergoing oral anticancer therapy (OAT), including side effects and medication errors.
- The ONCORAL program provides a structured care plan with weekly consultations to help manage these DRPs during the first OAT cycle, involving interventions from nurses and pharmacists.
- Results indicated that 87.1% of patients received interventions, identifying numerous DRPs and leading to adjustments in medications, with an average relative dose intensity of 83.1% for the treatment cycle.
Article Synopsis
- Elacestrant, an oral selective estrogen receptor degrader (SERD), has been shown to be superior to standard therapies for patients with ESR1-mutant tumors, based on the EMERALD trial results, and is now included in clinical guidelines.
- Access to elacestrant in Europe is subject to local health authority decisions, but it offers a significant benefit to certain patients by avoiding more aggressive treatments and improving their quality of life.
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Gynecol Oncol
October 2024
Article Synopsis
- The study analyzed how advanced ovarian cancer patients respond to niraparib maintenance therapy and patterns of disease recurrence.
- Of 314 patients, 190 developed new lesions, primarily in the peritoneum, lymph nodes, and liver, often seeing 1-3 new lesions upon progression.
- Findings suggest that while many patients develop oligometastatic disease at recurrence, further research is needed to assess if local therapies could enhance outcomes when combined with targeted maintenance therapy.